Glucagon-like peptide-1 receptor agonists, widely known as weight-loss and diabetes treatments like Ozempic and Wegovy, are currently being investigated by researchers as a potential treatment for drug and alcohol addiction. According to a randomized controlled trial published in The Lancet, these medications demonstrated robust therapeutic effects in patients with obesity and alcohol use disorder, reducing heavy drinking days by 41.1 percentage points compared to 26.4 points for a placebo group.
Clinical Trials and Large-Scale Data on GLP-1s and Addiction
The therapeutic potential of peptides like semaglutide and tirzepatide stems from how they mimic naturally occurring gut hormones to control digestion, blood sugar, and appetite. Because addiction can be likened to an abnormal appetite for a substance, researchers at bodies like the National Drug and Alcohol Research Centre (NDARC) are exploring whether these pathways alter cravings for alcohol, nicotine, cannabis, and opioids, according to conjoint professor of medicine Paul Haber.
Supporting clinical trials, a landmark study published earlier in the year in the BMJ analyzed observational data from more than 606,000 US veterans with type 2 diabetes. That study found that GLP-1 receptor agonists consistently lowered the risk of developing new substance use disorders. Furthermore, in patients with pre-existing addictions, the medication use correlated with fewer adverse clinical outcomes, including reduced emergency department visits, hospital admissions, overdoses, and overall mortality, as reported by NDARC director Professor Michael Farrell.
Pro Tip: Researchers emphasize that while data from large observational studies and clinical trials point toward promising outcomes, GLP-1 medications are still not officially licensed or approved for treating substance use disorders.
Patient Experiences and Real-World Cravings
Patients taking medications like Ozempic, Mounjaro, and Wegovy have reported abrupt shifts in their relationships with alcohol and other substances. Khaled Moussawi, MD, PhD, the Fields Professor of Pharmacology of Addiction in Neurology at the University of California, San Francisco (UCSF), noted that some clinical trial participants describe the cessation of cravings as flipping a “light switch.” UCSF chief of endocrinology and metabolism Suneil Koliwad, MD, PhD, recounted treating a retired executive who found alcoholic beverages so unappealing after starting Ozempic that he actively avoided social gatherings centered around drinks.
At the same time, experiences vary significantly among users. While some individuals report that their tolerance drops to zero or that alcohol makes them feel nauseous, others notice no change at all. For instance, a 20-year-old recent graduate named Faye Goodwin told reporters that quick onset of nausea hampered her social life when drinking, while a patient named Lisa noted she more than halved her weekly wine consumption since beginning Wegovy.
Medical Cautions and the Rebound Effect
Addiction specialists urge caution regarding the widespread off-label use of weight-loss drugs for substance dependence. GP and addiction specialist Dr. Chris Davis pointed out that a primary concern is what happens when patients stop taking the medication. Research shows that individuals regain an average of 60 percent of lost weight after cessation, raising the risk of a similar rebound in addictive behaviors or substance use, according to Davis.
Additional complications involve potential overlaps with eating disorders. Davis warned that if someone acquires Ozempic online to curb drinking while suffering from an underlying eating disorder or failing to eat properly, the outcome could be significantly detrimental to their health. Dr. Mary Ellen Harrod, chief executive of the NSW Users and AIDS Association, added that drug dependence involves complex social circumstances and past trauma that medicine alone may not address. Professor Haber estimates that conclusive results and any potential wider rollout of GLP-1s specifically for addiction remain five to ten years away.
Did You Know?
The process of finding new uses for existing medications is known as drug repurposing. Both Minoxidil, originally produced for hypertension, and Viagra, initially developed for chest pain, were successfully repurposed after clinical participants reported unexpected side effects.
Frequently Asked Questions
Are Ozempic and other GLP-1 drugs approved to treat addiction?
No. According to medical professionals, GLP-1 receptor agonists are not currently licensed or approved by regulators for treating substance use disorders, though clinical trials are underway.
How do GLP-1 medications affect alcohol cravings?
Medical researchers believe these drugs alter the reward response in the brain and suppress biological pathways related to appetite and craving, which can reduce the desire to keep drinking, according to studies published in The Lancet and the BMJ.
What happens to cravings if a patient stops taking GLP-1 drugs?
Specialists warn that just as patients often regain weight after stopping weight-loss peptides, there is a risk that addictive behaviors or substance use could rebound upon cessation.
Where can people seek help for alcohol or drug dependence?
For free and confidential advice about alcohol and other drugs, individuals can contact dedicated support services such as the National Alcohol and Other Drug hotline at 1800 250 015.
What are your thoughts on repurposing diabetes and weight-loss drugs for addiction treatment? Join the conversation by leaving a comment below, and subscribe to our newsletter for the latest medical research updates.
Worth a look